EmPRO’s Annual Patient Safety Conference – A Medical Malpractice Mock Trial
- Patient Safety
November 21 @ 9:00 am - 3:30 pm
Learning Objectives:
- Explain the components that comprise a malpractice lawsuit.
- Examine the role that families play in the initiation of malpractice cases.
- Explain the importance of documentation and how it can affect the defensibility of a malpractice case.
- Identify areas within healthcare facilities that are most susceptible/prone to liability.
- Develop and implement organizational practices/procedures to mitigate future liability claims.
- Implement practices/procedures that will assist in the defense of your case in the event of litigation.
Continuing Education Credits:
This program has been approved for Continuing Education for 6 total participant hours by NAB/NCERS—Approval #20251120-6-A106104-IN.
Accreditation Statement:
EmPRO Insurance Company is accredited by The Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians.
EmPRO Insurance Company designates this live course for maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement:
EmPRO Insurance Company asks all individuals involved with content development, planning, and management to disclose all financial relationships with any ineligible companies that they have had for the past 24 months. There is no minimum financial threshold; all financial relationships, regardless of the amount, with an ineligible company must be disclosed.
The ACCME defines an ineligible company: as companies whose primary business is producing, marketing, selling, re-selling healthcare products used by or on patients.
Should any relevant financial relationship(s) with an ineligible company be identified, it will be mitigated prior to the activity.
The faculty and planners for this live course from Benvenuto & Gaujean and the EmPRO Risk Management Department, have no relevant financial relationship(s) with ineligible companies within the past 24 months to disclose.